Systemic bevacizumab for aggressive recurrent respiratory papillomatosis: A single center experience of five cases.

• DOI: 10.1200/jco.2022.40.16_suppl.e22005
• Publication Date: 2022-06-06T17:28:06Z
• Authors: Zengjun Liu; Yang Xiao; Jing Xu; Dongyuan Zhu
• Keywords: Recurrent Respiratory Papillomatosis; Debulking

e22005 Background: Recurrent respiratory papillomatosis (RRP) is a human papillomavirus (HPV) driven benign neoplasm, affecting larynx, trachea, and even lung, leading to voice disorders, airway obstruction, post-obstructive pneumonia. Currently, there no curative therapy for RRP.Patients require frequent debulking operations symptomatic palliation. However, several case reports documented promising results on inhibition of vascular endothelial growth factor (VEGF) by systemic administration bevacizumab. Methods: We retrospectively analyzed clinical, radiological, bronchoscopy data aggressive RRP patients treated with bevacizumab since January 2021. Results: 5 consecutive were included. Median age (range) was 8 (4-30), 60% (3/5) male. The locations as follows: localized in the major (including vocal cords, main bronchus), n = 1; extensive from lung parenchyma, 4. median number local interventions (2-17) throughout 12 months prior treatment. therapeutic agents, such HPV vaccine interferon had been tried two patients. Bevacizumab administered at dose mg/kg (n 4) or 7.5 1) intravenously. Treatment intervals initiated every 2-3 weeks subsequently extended after achieving maximum response. received 6 cycles (range 4-7). given adjuvant 2 3 rd th day laser operation, salvage other All displayed improvement disease burden. No required surgery during medain 7 3-8) follow up periods initiating A rapid response demonstrated patient long-standing pulmonary disease. Except mild transit abdominal pain hemoptysis patients, treatment well tolerated. Conclusions: Inhibition VEGF seems be tolerated effective option forms RRP.